Last10K.com

Aeolus Pharmaceuticals, Inc. (AOLS) SEC Filing 10-K Annual report for the fiscal year ending Friday, September 30, 2016

Aeolus Pharmaceuticals, Inc.

HISTORY TOOLS
CIK: 1261734 Ticker: AOLS
Document and Entity Information - USD ($)
12 Months Ended
Sep. 30, 2016
Dec. 16, 2016
Mar. 31, 2016
Document And Entity Information   
Entity Registrant NameAEOLUS PHARMACEUTICALS, INC.  
Entity Central Index Key0001261734  
Document Type10-K  
Document Period End DateSep. 30, 2016  
Amendment Flagfalse  
Current Fiscal Year End Date--09-30  
Is Entity a Well-known Seasoned Issuer?No  
Is Entity a Voluntary Filer?No  
Is Entity's Reporting Status Current?Yes  
Entity Filer CategorySmaller Reporting Company  
Entity Common Stock, Shares Outstanding 152,085,825 
Public Float  $ 10,925,560
Document Fiscal Period FocusFY  
Document Fiscal Year Focus2016  

View differences made from one year to another to evaluate Aeolus Pharmaceuticals, Inc.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 10-K Annual Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Aeolus Pharmaceuticals, Inc..

Continue

Assess how Aeolus Pharmaceuticals, Inc.'s management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Aeolus Pharmaceuticals, Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2016 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors

Continue

SEC Filing Tools

Financial Statements, Disclosures and Schedules

Inside this 10-K Annual Report

Document And Entity Information
Condensed Consolidated Balance Sheets (unaudited)
Condensed Consolidated Balance Sheets (unaudited) (parenthetical)
Condensed Consolidated Statements Of Cash Flows (unaudited)
Condensed Consolidated Statements Of Operations (unaudited)
Consolidated Statements Of Stockholders Equity (deficit)
A. Organization, Business And Summary Of Significant Accounting Policies
B. Organization, Business And Summary Of Significant Accounting Policies (policies)
B. Organization, Business And Summary Of Significant Accounting Policies (tables)
B. Summary Of Significant Accounting Policies
B. Summary Of Significant Accounting Policies - Fair Value (details)
B. Summary Of Significant Accounting Policies - Net Income (loss) Per Common Share (details)
B. Summary Of Significant Accounting Policies - Warrant Fair Value (details 1)
C Liquidity (details Narrative)
C. Liquidity
D. Investments
D. Investments (details Narrative)
E. Commitments
F. Debt
G. Stockholder's Equity (tables)
G. Stockholders' Equity (deficit)
G. Stockholders' Equity - Warrant Activity (details 2)
G. Stockholders' Equity - Warrants (details)
H. Stock-based Compensation
H. Stock-based Compensation (details 3)
H. Stock-based Compensation (details 4)
H. Stock-based Compensation (details Narrative)
H. Stock-based Compensation (tables)
H. Stock-based Compensation - Details Of Stock Options (details 2)
H. Stock-based Compensation - Nonvested Options (details 1)
H. Stock-based Compensation - Stock Option Activity (details)
I. Income Taxes
I. Income Taxes (details 1)
I. Income Taxes (details 2)
I. Income Taxes (details 3)
I. Income Taxes (details)
I. Income Taxes (tables)
J. Contingencies
K. Agreements
L. Litigation
M. Recently Issued Accounting Pronouncements
Ticker: AOLS
CIK: 1261734
Form Type: 10-K Annual Report
Accession Number: 0001199073-16-000300
Submitted to the SEC: Tue Dec 20 2016 5:22:16 PM EST
Accepted by the SEC: Tue Dec 20 2016
Period: Friday, September 30, 2016
Industry: Pharmaceutical Preparations

External Resources:
Stock Quote
Social Media
SEC.gov

Bookmark the Permalink:
https://last10k.com/sec-filings/aols/0001199073-16-000300.htm